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Erosive and osteoarthritic structural progression in
early rheumatoid arthritis
Daniel F. McWilliams1,2, Michelle Marshall3, Keeranur Jayakumar4,
Sally Doherty2, Michael Doherty1,2, Weiya Zhang1,2, Patrick D. W. Kiely5,
Adam Young6 and David A. Walsh1,2,7
Abstract
Objectives. To investigate factors associated with joint damage in early RA, and how comorbid OA might
influence patient assessment and outcomes.
Methods. Baseline radiographs of hands and feet from 512 participants in the Early RA Network cohort,
and after 3 (±1) years, 166 of those participants yielded complete scores for RA [erosions, joint space
narrowing (JSN)] and OA [JSN, osteophytes (OST)] using validated atlases. DAS28-P is the proportion of
DAS28 attributed to patient-reported factors. Adjusted odds ratios were calculated using logistic
regression.
Results. OA was common at baseline in early RA (40% hand and 48% foot) and associated with RA
radiographic score. Higher baseline RA scores were associated with increasing age and ESR, and lower
DAS28-P. OST scores were associated with higher age. DAS28 and patient-reported outcomes improved,
whereas RA and OA radiographic scores deteriorated by follow-up. Erosive progression was predicted by
higher baseline erosions, female gender, better mental health and lower DAS28-P. Hand OST progression
was predicted by baseline OST scores. Inflammatory disease activity was associated with erosive, but not
with OA progression. Baseline hand OA predicted worse physical function at follow-up, but radiographic
progression did not explain changes in patient-reported outcomes.
Conclusion. OA is a common comorbidity that might confound radiographic and clinical assessment, but
does not fully explain erosive progression or patient-reported outcomes in early RA. Early RA management
should address psychosocial factors and comorbidities, as well as joint inflammation.
Key words: rheumatoid arthritis, osteoarthritis, osteophyte, erosions, hands, feet
Rheumatology key messages
. Radiographic OA is common in early RA, and might confound RA assessment.
. RA and OA structural damage might both progress during early RA, despite other clinical improvements.
. Patient-reported measures might also be useful for stratifying those at risk of erosive RA progression.
Introduction
OA is prevalent in the ageing population, including those
in whom RA first becomes apparent [1]. OA might con-
found RA assessment, being a comorbid source of joint
pain, and either diagnosis might moderate pathogenesis
of the other disease. Inflammatory RA might suppress
osteophytosis [2], whereas suppression of RA inflamma-
tion with biologics reduces structural OA [3].
The DAS28 is commonly used to measure inflammatory
disease activity, and inform treatment/response decisions
[4, 5]. Although interpreted as a measure of inflammation,
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DAS28 is also increased in people with RA who have con-
current FM [6]. We have recently derived the DAS28-P
index, which is the proportion of DAS28 attributed to pa-
tient-reported factors [7]. DAS28-P was associated with
higher tender joint count (TJC), visual analogue scale 
general health (VASGH), sensitivity to pain and worse
pain progression in RA, as well as poorer mental health
and fatigue scores [8]. This study aimed to elucidate as-
sociations between joint damage, inflammation, pain and
disability in people with early RA, and explore how comor-
bid OA might influence patient assessment and
outcomes.
Methods
Patients and recruitment
The ERAN inception cohort [9, 10] was recruited from out-
patient centres in the UK and Eire [10, 11] 200214.
Patients were recruited following their first diagnosis of
RA by a rheumatologist, and were not required to satisfy
1987 ACR RA criteria (46% at baseline and 45% at follow-
up fulfilled the criteria). Participants were monitored, trea-
ted and underwent radiography according to clinical need
guided by a schedule agreed by consensus prior to cohort
recruitment. At baseline, 41% were treated with MTX
monotherapy, 25% SSZ monotherapy and 24% a com-
bination of non-biologic DMARDs. Glucorticoid use was
reported in 19% of participants at baseline. This study
was approved by Trent Research Ethics Committee (ref
01/4/047), and all participants gave signed, informed con-
sent in line with the Declaration of Helsinki.
Data collection
Standardized demographic and disease activity data were
collected at baseline, 36 months, 1 year and yearly from
baseline thereafter. Seropositive was defined as positive
or strongly positivity for RF or antibodies to citrullinated
proteins using local laboratory ranges. Participants also
completed Short Form 36 (SF36) [12] and HAQ disability
index [13] questionnaires. The DAS28-P index was calcu-
lated as the proportion of DAS28 attributed to patient-
reported factors (TJC and VASGH) in people with
active RA (DAS28>3.2) [7].
Radiography
Plain radiographs of hands (anterior posterior) and feet
(dorsoplantar) were collected from six centres with high
recruitment to ERAN (Wye Valley National Health Service
(NHS) Trust, Sherwood Forest Hospitals NHS Foundation
Trust, West Hertfordshire Hospitals NHS Trust, University
Hospitals of Morecambe Bay NHS Foundation Trust,
Yeovil District Hospital NHS Foundation Trust and North
Bristol NHS Trust). Radiographic images were from elec-
tronic data stores, or radiographic films were scanned
using an Epson Expression 10000XL (Seiko Epson,
Japan). Participants were representative of those recruited
at the selected ERAN centres for whom baseline radio-
graphs were not collected (data not shown); baseline radio-
graphic scores did not differ significantly between the
patients attending the different study centres (data not
shown). Compared with those who only provided baseline
images, people providing follow-up images were older at
baseline (mean 60 vs 55 years; P< 0.001); had higher
DAS28 (mean 4.8 vs 4.4; P< 0.036); and were less likely
to be current smokers (29 vs 41%; P = 0.012). Baseline
radiographic scores did not differ significantly between
those who provided follow-up images and those who pro-
vided baseline images only (data not shown).
RA radiographic scoring
Images of hands and feet were scored for erosions and
joint space narrowing (JSN) using the van der Heijde
modification of Sharp’s method [14, 15] for erosions and
JSN [16]. Hand PIP joints, MCP joints, CMC 35, thumb
base, radiocarpal joint, capitatenavicularlunate joints,
multangular navicular, trapezium/trapezoid MTP and the
hallux IP joints were assessed. Erosions were defined as
regions with breakage or severe disruption of the
intracapsular marginal cortical bone. Summated erosion
and JSN scores give a total ranging from 0 to 448, with a
maximum erosion score of 280 and JSN score of 168 [17].
A 5-point progression in total score within 1 year is con-
sidered clinically important [18].
Scoring was performed by one scorer (D.McW.), who
prior to the study was compared with an experienced
scorer (K.J.) [19] using 25 sets of hand and foot radio-
graphs from the Early Rheumatoid Arthritis Study cohort
[20]. Intraclass correlation coefficients (ICCs) for interob-
server variation were 0.80 (0.600.90) for erosions and
0.75 (0.570.86) for total/summated score (P< 0.001 for
all). Intra-observer ICCs were 0.92 (0.820.97) and 0.95
(0.870.98), respectively.
OA radiographic scoring
Validated radiographic scoring methods were used for
hands [21, 22] and feet [23]. At both sites, osteophytes
(OST) and JSN were scored on a scale of 03 with refer-
ence to a photographic atlas. For hand OA, scoring was
performed for DIP joints, PIP joints and the first CMC joint.
Foot OA scoring was performed on MTP1, cuneometatar-
sal joints 1 and 2, the cuneonavicular joint and the talo-
navicular joint (JSN only). Additionally, hand OA was
classified when a joint from the hand OA atlas showed
Kellgren and Lawrence grade52 [24], and grades were
also recorded for thumb (IP and metacarpal) and MCP
joints (digits 25). Foot OA was classified when any joint
from the foot OA atlas showed an OST score52 [23].
The single observer (D.McW.) was compared with an
experienced scorer (S.D.), using 20 pairs of hands from
the GOAL study [25]. Summated joint scores for the whole
hand, DIP and PIP joints had interobserver ICCs (95% CI)
of 0.78 (0.530.91), 0.89 (0.740.95) and 0.78 (0.520.91),
respectively (P< 0.001). Intra-observer ICCs (95% CI)
were 0.94 (0.720.96), 0.98 (0.930.99) and 0.98
(0.960.99), respectively. Foot OA scoring by the single
scorer (D.McW.) was compared with that of an experi-
enced scorer (M.M.) using 60 pairs of feet from the
CAS-F study [26]. For summated OST scores, inter-
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observer ICC (95% CI) was 0.81 (0.690.89), and intra-
observer ICC (95% CI) was 0.84 (0.580.94).
ERAN study participants were assessed in a blinded,
random order, with images from different centres ran-
domly mixed. However, radiographs were viewed chrono-
logically for each person [14]. Baseline radiographs were
within one calendar year of the baseline visit. A total of 512
people had at least one baseline radiograph, which
yielded 459 pairs of fully scoreable hands and feet at
baseline. Follow-up radiographs were selected from the
3 (1) year follow-up time point, giving a final sample size of
166 people with hand and foot radiographs scored at
baseline and follow-up.
Statistical analysis
Radiographic scores, and their progression were primary
outcome variables, and complete case analysis was per-
formed. Each outcome variable was divided by the median
for the calculation of odds ratios (ORs), adjusted ORs
(aORs) and 95% CIs. Spearman’s rank correlation coeffi-
cients were calculated for analysis during follow-up.
Baseline DAS28 scores were classified into EULAR dis-
ease activity groups [Low: 03.19 (for whom DAS28-P is
not calculated [7]), moderate: 3.205.19 and high:5 5.20)
[27]; BMI was classified into World Health Organisation
(WHO) groups (<25; 25.029.9;530) [28]. Other continu-
ous variables were divided into tertiles of increasing sever-
ity. Univariate analyses were not adjusted for multiple
comparisons. Logistic regression models were all adjusted
for age, gender, either DAS28 or all four DAS28 compo-
nents, and length of follow-up (23 or 34 years).
Additionally, they were adjusted for those variables with
P< 0.10 in univariate analysis. For cross-sectional logistic
regression analyses of baseline-only data, adjusting vari-
ables were selected (RA radiographic scores—DAS28-P;
or ESR, swollen joint count (SJC), TJC and VASGH, plus
symptom duration (erosions only) or mental health (JSN
only). Hand OA—DAS28-P, serology and symptom dur-
ation (all), plus mental health (OST only) or physical func-
tion (JSN only). Foot OA—DAS28P (all), plus HAQ (OST
only) or serology, mental health, bodily pain, vitality and
physical function (JSN only). Analysis of baseline hand
OA and disability at 3 years were adjusted for the baseline
disability measure (HAQ or SF36physical function), age,
gender and DAS28. Statistical analysis was performed
using SPSS version 21 (IBM Corp, USA). Statistical signifi-
cance was taken when P< 0.05.
Results
Demographics and clinical characteristics
The baseline characteristics of the study group are shown
in Table 1.
Cross-sectional associations of baseline radiographic
scores
The radiographic scores are shown in Table 2. The median
(interquartile range; IQR) RA score was 6 (412), the hand
OST score was 9 (05) and the foot OST score was 2
(14). Patients with erosive changes on hand or foot radio-
graphs displayed higher OA radiographic scores, both for
OST and for JSN, both in hands and in feet (Table 2).
Furthermore, OA was observed within DIP joints in 30%
of cases, in PIP joints in 12% and in the thumb base in
13% of cases. In the foot, OA in MTP1 was observed in
44% of cases and in cuneometatarsal 1 joint in 4% of
cases. Evidence of OA was also observed in joints
beyond the scope of the OA atlases, with OA in MCP
joints in 19%, in the thumb IP joint in 15%, in MTP25 in
6% and in hallux IP joints in 4% of cases. RA and OA
radiographic changes were occasionally observed within
the same joint (supplementary Fig. S1, available at
Rheumatology Online).
Univariate analyses were used to explore cross-
sectional associations at baseline (Table 3). Age was con-
sistently associated with higher radiographic scores, and
DAS28-P was associated with lower radiographic scores
in most measures (Table 3). Symptom duration, serology
and ESR were also associated with some of the radio-
graphic scores.
Further analysis at baseline was performed, using logis-
tic regression to assess which factors were independently
associated with baseline radiographic scores. Baseline
erosion score was associated [aOR (95% CI)] with age
TABLE 1 Baseline demographic and clinical characteris-
tics of study population
Variable
All cases with base
line radiographs
Demographics
N 512
Female 65%
Age, median (IQR), years 58 (4869)
BMI, kg/m2 26.8 (24.130.5)
Smoking history 62%
RA disease characteristics
Duration, median (IQR), months 6 (312)
Seropositive 62%
DAS28, median (IQR), 4.6 (3.45.7)
VASGH, 0100 mm, median (IQR) 40 (2062)
TJC, 028, median (IQR) 5 (111)
SJC, 028, median (IQR) 4 (18)
ESR, median (IQR), mm/h 20 (1137)
CRP, median (IQR), ng/dl 7 (320)
DAS28-P, median (IQR) 0.45 (0.380.50)
Patient-reported outcome measures
HAQ, 03, median (IQR), 1.0 (0.41.5)
SF36bodily pain, mean (S.D.) 35 (11)
SF36physical function, mean (S.D.) 31 (15)
SF36vitality, mean (S.D.) 43 (11)
SF36mental health, mean (S.D.) 47 (11)
SF36 scores represent normed values, where normal UK
population values are mean (S.D.) 50 (10). Seropositive was
defined as positive for RF and/or citrullinated proteins.
DAS28-P: proportion of patient-reported components in
the DAS28 index, n: number, VASGH: visual analogue
scale  general health.
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[2.57 (1.77, 3.72)], longer duration [1.49 (1.06, 2.29)] and
lower DAS28-P [0.68 (0.48, 0.97)]. Analysis after the inclu-
sion of ESR, SJC, TJC and VASGH, and removal of
DAS28 and DAS28-P, showed that erosions were asso-
ciated with higher ESR [1.77 (1.26, 2.47)] and lower TJC
scores [0.63 (0.43, 0.93)]. Similar analysis of OA at base-
line showed that age was independently associated with
higher OST score (aOR 3.93, 95% CI: 2.39, 6.47;
P< 0.001). Higher OA JSN score in the hands was asso-
ciated with greater age (aOR 3.37, 95% CI: 2.08, 5.47;
P< 0.001) and female gender (aOR 2.36, 95% CI: 1.16,
4.78; P = 0.018). At baseline, age was associated with
higher foot OST scores (aOR 3.02, 95% CI: 2.11, 4.34;
P< 0.001). Foot JSN scores were associated with age
(aOR 1.93, 95% CI: 1.19, 3.14; P = 0.008) and female
gender (aOR 2.16, 95% CI: 1.05, 4.46; P = 0.036).
Radiographic progression in early RA
At the 3 (±1) year follow-up there were n = 166 cases that
provided radiographic images with scores [median (IQR)]
of total: 14 (723), erosions: 5 (210) and JSN: 7 (413).
These represented increases of total: 6 (312), P< 0.001;
erosions: 3 (16), P< 0.001 and JSN: 3 (17), P< 0.001. Of
the 166 participants, 148 (89%) had one or more erosions
in either hands (80%) or feet (65%), and people with ero-
sions scored at follow-up were significantly older than
those without (mean age 57 vs 45 years, P< 0.05).
Radiographic OA scores [median (IQR)] at follow-up
were hand OST: 1 (07) and JSN: 1 (03), and foot OST:
2 (14) and JSN: 4 (35). Hand OST progressed by 0 (02),
P< 0.001 and foot OST by 0 (01), P< 0.001. Hand OA
JSN progressed by 0 (01), P = 0.046 and foot JSN by 1
(1, 2), P< 0.001 (Table 2). At follow-up, 41% (68/166) of
participants were classified as having hand OA, and 47%
(78/166) had foot OA. Hand OA and foot OA were newly
classified at follow-up in, respectively, 15% (17/111) and
25% (24/96) of participants who were not classified as
having OA at baseline. Further examination of OA pro-
gression showed that those people without OSTs at
baseline in scored hand or foot joints progressed to KL
score classification as hand OA or foot OA in 4% (4/92)
and 3% (3/33) of cases, respectively. Radiographs that
were scored JSN = 0 and OST = 0 at baseline were rare
in those with OA at follow-up. Of the 74 with hand OA at
follow-up, 1 (1.4%) had no JSN and no OST at baseline.
Predictors of radiographic progression in early RA
Table 4 presents the univariate analyses of baseline char-
acteristics associated with greater changes in radiographic
scores. Age and radiographic scores were the only base-
line variables significantly associated with changes in total
or JSN RA radiographic scores. Increases in erosion
scores were associated with higher age, higher baseline
erosion score, more hand OA, lower DAS28-P and better
vitality and mental health (Table 4). Changes in hand OST
scores were predicted at the univariate level by higher age,
higher baseline TJC, hand OST score and foot OST score
(Table 4). Greater changes in foot OST scores were asso-
ciated with baseline hand OST scores (Table 4). Univariate
analysis of OA JSN scores is shown in supplementary
Table S1, available at Rheumatology Online.
Multivariable logistic regression was used to examine
the data for independent predictors of higher than
median radiographic change. Above median increases in
erosion scores were predicted by higher baseline erosions
score, female gender, better mental health and lower
DAS28-P (Table 5). Greater than median OST score pro-
gression for the hands was predicted by baseline hand
OST score only (Table 5).
Clinical associations of radiographic change in early
RA
To investigate the contribution of inflammatory disease
activity to radiographic progression, cumulative values
for DAS28 or its components were calculated from base-
line to year 2. Higher cumulative ESR was associated with
greater RA radiographic progression, but not with OA
progression (supplementary Table S2, available at
TABLE 2 Baseline radiographic scores in early RA (univariate comparisons)
Study group
Erosions in hand or foot 51 Hand K 5L2 OA Foot osteophyte scored 52
Total No Yes No Yes No Yes
Radiographic scores
Erosions (%) 72 0 100 65 83** 64 81**
RA score 6 (412) 2 (14) 8 (515) 4 (28) 11 (621)** 5 (28) 8 (416)**
Erosion score 2 (05) 0 (00) 3 (26) 1 (03) 3 (18)** 1 (03) 3 (16)**
JSN score (RA) 4 (28) 2 (14) 5 (210)** 3 (15) 6 (412)** 3 (16) 5 (311)**
Hand OA (%) 40 24 46** 0 100 30 52**
Hand OST score 1 (05) 0 (02) 2 (06)** 0 (01) 6 (310)** 0 (03) 2 (06)**
Hand JSN score 1 (03) 0 (01) 1 (03)** 0 (01) 3 (16)** 0 (02) 1 (03)**
Foot OA (%) 48 33 54** 39 61** 0 100
Foot OST score 2 (14) 2 (03) 2 (14)** 2 (03) 3 (25)** 1 (02) 4 (35)**
Foot JSN score 4 (25) 3 (24) 5 (210)** 3 (25) 4 (36)** 3 (25) 4 (36)**
Baseline radiographic scores and radiographic classifications [median (IQR)] or percentage. **P< 0.01, *P<0.05 in Yes vs No
comparisons (univariate, unadjusted analyses).
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TABLE 4 Radiographic progression in early RA (univariate analyses)
Erosions and
osteophytes
Above/below median
change in erosion
score (24 years)
Above/below median
change in hand
OST score
Above/below median
change in
foot OST
OR (95% CI) OR (95% CI) OR (95% CI)
Demographics
Gender: female 1.10 (0.58, 2.08) 0.99 (0.52, 1.87) 1.39 (0.73, 2.67)
Age, years
Low tertile 1 1 1
Middle tertile 2.55 (1.18, 5.51)* 1.85 (0.84, 4.09) 0.79 (0.37, 1.70)
High tertile 3.68 (1.66, 8.15)** 3.72 (1.70, 8.15)** 1.57 (0.73, 3.35)
BMI, kg/m2
<25 1 1 1
2529.99 1.19 (0.55, 2.57) 1.05 (0.49, 2.24) 1.24 (0.57, 2.70)
30+ 1.05 (0.45, 2.45) 1.35 (0.59, 3.10) 1.20 (0.51, 2.86)
Smoking history
Yes 0.89 (0.47, 1.68) 0.72 (0.38, 1.34) 0.57 (0.30, 1.07)
Disease characteristics and
RA measures
Symptom duration (months)
Low tertile 1 1 1
Middle tertile 1.05 (0.47, 2.34) 1.29 (0.60, 2.77) 0.95 (0.44, 2.04)
High tertile 1.88 (0.88, 4.01) 1.34 (0.62, 2.87) 0.85 (0.39, 1.88)
Serology
Seropositive 1.85 (0.87, 3.92) 0.74 (0.35, 1.55) 1.11 (0.52, 2.38)
DAS28ESR
<3.2 1 1 1
3.25.19 2.13 (0.79, 5.69) 1.00 (0.38, 2.64) 1.22 (0.46, 3.22)
5.2+ 2.57 (0.95, 6.98) 1.84 (0.70, 4.82) 1.59 (0.61, 4.15)
VASGH (0100 mm)
Low tertile 1 1 1
Middle tertile 0.66 (0.30, 1.42) 0.48 (0.22, 1.03) 0.69 (0.32, 1.48)
High tertile 0.83 (0.39, 1.75) 0.64 (0.31, 1.33) 0.63 (0.29, 1.35)
TJC (028)
Low tertile 1 1 1
Middle tertile 1.75 (0.83, 3.71) 1.94 (0.88, 4.25) 1.21 (0.56, 2.61)
High tertile 0.96 (0.44, 2.08) 2.91 (1.32, 6.41)* 1.16 (0.54, 2.52)
SJC (028)
Low tertile 1 1 1
Middle tertile 1.65 (0.77, 3.50) 1.24 (0.58, 2.66) 0.96 (0.45, 2.09)
High tertile 1.56 (0.74, 3.26) 1.36 (0.66, 2.77) 1.34 (0.64, 2.79)
ESR (mm/h)
Low tertile 1 1 1
Middle tertile 1.50 (0.65, 3.48) 0.85 (0.37, 1.94) 1.43 (0.62, 3.26)
High tertile 2.13 (0.94, 4.82) 1.29 (0.58, 2.85) 1.26 (0.55, 2.88)
CRP (ng/dl)
Low tertile 1 1 1
Middle tertile 0.81 (0.31, 2.17) 1.42 (0.50, 4.08) 0.72 (0.27, 1.97)
High tertile 1.00 (0.39, 2.59) 1.25 (0.48, 3.25) 1.77 (0.67, 4.67)
DAS28P
Low tertile 1 1 1
Middle tertile 0.46 (0.18, 1.17) 0.41 (0.17, 1.00) 1.00 (0.41, 2.47)
High tertile 0.33 (0.13, 0.85)* 0.81 (0.34, 1.98) 0.77 (031, 1.92)
Outcome measures
HAQ, 03
Low tertile 1 1 1
Middle tertile 1.17 (0.53, 5.59) 1.41 (0.65, 3.06) 0.99 (0.46, 2.14)
High tertile 0.93 (0.44, 1.96) 1.06 (0.48, 2.36) 0.59 (0.26, 1.33)
SF36bodily pain
Good tertile 1 1 1
Middle tertile 1.06 (0.44, 2.58) 0.81 (0.37, 1.77) 0.54 (0.24, 1.22)
Poor tertile 0.47 (0.20, 1.07) 1.03 (0.42, 2.50) 0.68 (0.27, 1.69)
(continued)
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TABLE 4 Continued
Erosions and
osteophytes
Above/below median
change in erosion
score (24 years)
Above/below median
change in hand
OST score
Above/below median
change in
foot OST
OR (95% CI) OR (95% CI) OR (95% CI)
SF36physical function
Good tertile 1 1 1
Middle tertile 1.23 (0.52, 2.91) 1.30 (0.58, 2.90) 1.41 (0.61, 3.24)
Poor tertile 0.66 (0.29, 1.49) 1.00 (0.44, 2.27) 1.06 (0.45, 2.50)
SF36-vitality
Good tertile 1 1 1
Middle tertile 0.50 (0.21, 1.16) 1.28 (0.57, 2.89) 0.51 (0.22, 1.19)
Poor tertile 0.39 (0.16, 0.94)* 0.84 (0.36, 1.95) 1.05 (0.44, 2.48)
SF36mental health
Good tertile 1 1 1
Middle tertile 0.68 (0.29, 1.55) 0.64 (0.29, 1.43) 0.46 (0.20, 1.05)
Poor tertile 0.28 (0.12, 0.68)** 0.65 (0.28, 1.47) 0.95 (0.41, 2.21)
Radiographic scores
RA total score
Low tertile 1 1 1
Middle tertile 2.42 (1.12, 5.20)* 1.31 (0.61, 2.81) 1.19 (0.55, 2.57)
High tertile 5.47 (2.44, 12.27)** 2.22 (1.03, 4.78) 1.57 (0.73, 3.40)
Erosion score
Low tertile 1 1 1
Middle tertile 1.65 (0.77, 3.58) 1.31 (0.60, 2.85) 0.70 (0.32, 1.52)
High tertile 4.59 (2.01, 10.50)** 1.95 (0.89, 4.31) 1.18 (0.54, 2.59)
Hand OST
Low tertile 1 1 1
Middle tertile 2.72 (1.17, 6.32) 2.15 (0.93, 4.96) 0.31 (0.12, 0.83)*
High tertile 1.75 (0.86, 3.58) 7.19 (3.35, 15.43)** 2.16 (1.04, 4.50)*
Foot OST
Low tertile 1 1 1
Middle tertile 0.94 (0.46, 1.91) 2.15 (0.93, 4.96) 0.65 (0.32, 1.32)
High tertile 1.46 (0.64, 3.33) 7.19 (3.35, 15.43)** 0.62 (0.28, 1.37)
Baseline variables and their univariate, unadjusted associations with progression of erosions and osteophyte scores in those
patients with follow-up images. Follow-up radiographic change scores were dichotomized into above and below median for
generation of odds ratios (ORs) and 95% CIs. The risks for above median changes are shown. Structural change was divided
into above/below median and OR (95% CI) calculated. Variables with significant results are highlighted in bold. **P< 0.01.
*P< 0.05. VASGH: visual analogue scale  general health.
TABLE 5 Logistic regression for structural change in early RA
Erosive progression
(hands and feet)
Hand osteophyte
progression
Foot osteophyte
progression
aOR (95% CI) P-value aOR (95% CI) P-value aOR (95% CI) P-value
Age, years 1.76 (0.64, 4.80) 0.271 0.78 (0.35, 1.72) 0.532 1.31 (0.53, 3.22) 0.555
Female 4.54 (1.28, 16.08) 0.019 0.77 (0.29, 2.03) 0.599 2.14 (0.75, 6.09) 0.158
DAS28 1.19 (0.34, 4.19) 0.789 1.78 (0.68, 4.68) 0.241 1.17 (0.40, 3.43) 0.782
SF36bodily pain 0.86 (0.39, 1.89) 0.713 Not used Not used
SF36mental health 0.45 (0.20, 1.00) 0.049 Not used Not used
SF36vitality 1.25 (0.51, 3.01) 0.629 Not used Not used
DAS28-P 0.45 (0.22, 0.90) 0.025 0.77 (0.42, 1.41) 0.396 1.36 (0.71, 2.59) 0.350
RA radiographic score Not used 0.85 (0.47, 1.54) 0.598 1.38 (0.71, 2.67) 0.343
Erosions 2.14 (1.02, 4.50) 0.044 Not used Not used
Hand OST 0.68 (0.30, 1.55) 0.354 2.46 (1.26, 4.80) 0.008 1.16 (0.59, 2.31) 0.670
Foot OST 0.89 (0.44, 1.83) 0.757 1.15 (0.62, 2.14) 0.652 0.64 (0.32, 1.26) 0.197
Duration of follow-up, years 1.15 (0.39, 3.35) 0.802 1.09 (0.41, 2.93) 0.865 1.83 (0.64, 5.17) 0.257
Logistic regression models, adjusted for baseline factors, and the risk of higher-than-median progression of erosions and
osteophytes (n = 166). Significant results highlighted in bold.
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Rheumatology Online). Higher cumulative DAS28 or
VASGH were both associated with increased JSN
changes for RA (hands and feet combined) and also for
OA foot scores (supplementary Table S2, available at
Rheumatology Online). Progression of OST radiographic
scores was not significantly associated with cumulative
DAS28 or any of its components (supplementary Table
S2, available at Rheumatology Online).
At the 3-year follow-up, we investigated whether the
presence of OA at baseline was associated with worse
clinical outcome. Hand OA at baseline was associated
with worse SF36physical function at follow-up [hand
OA: 30 (14) vs no hand OA 37 (15), P = 0.001] and worse
HAQ disability scores at follow-up [hand OA: 1.1 (0.8) vs
no hand OA 0.8 (0.7), P = 0.015]. Adjustments for confoun-
ders removed the significance of these associations
[Physical Function b = 3.0 (95% CI: 9.2, 3.2,
P = 0.336 and HAQ b= 0.2 (95% CI: 0.1, 0.4,
P = 0.197)]. Corresponding univariate or multivariable as-
sociations were not significant between baseline hand OA
and bodily pain or DAS28, or between foot OA classifica-
tion and any clinical outcome. Furthermore, we investi-
gated whether changes in radiographic scores may
mediate clinical outcome in early RA. Progression of RA
and OA radiographic scores were not significantly asso-
ciated with worsening in SF36 Physical Function score,
HAQ disability or SF36 Bodily Pain score, even after ad-
justing for change in DAS28 (all standardized beta
values<0.23, P50.091).
Discussion
We found that radiographic OA was common in early RA,
and RA and OA structural progression both occurred
during the first 3 years after diagnosis. Associations be-
tween RA and OA structural changes indicate that comor-
bid OA might confound disease assessment in people
with early RA. Inflammation might mediate erosive pro-
gression, but non-inflammatory factors measured using
mental health scores and DAS28-P moderate the ability
of DAS28 to predict erosive progression in early RA.
Factors such as DAS28-P or mental health deserve inves-
tigation as novel stratification tools for treatments target-
ing radiographic progression in early RA.
Sustained inflammatory disease activity causes erosive
progression in RA [29, 30]. A majority (61%) of participants
with follow-up radiographs displayed RA radiographic
progression of a magnitude considered clinically import-
ant [18]. This might reflect inadequate disease suppres-
sion by monotherapies commonly used at the time of
patient recruitment [31], and selection bias for those
with more active inflammatory disease. Previous attempts
to predict erosive progression in RA have focused on
those factors anticipated to augment RA pathogenesis
[32]. Baseline radiographic scores predicted radiographic
progression, supporting the early classification of patient
subgroups as either erosive/non-erosive [33], or either
osteoarthritic/non-osteoarthritic. Inflammation, seroposi-
tive status and erosions have been associated with early
RA [34]. However, high baseline inflammatory disease
activity might be associated with a greater potential to
respond to treatment [35] or a greater likelihood of alloca-
tion to more intensive treatment in routine clinical practice
[31]. Seropositivity and DAS28 were not independent pre-
dictors of subsequent radiographic progression in our
study, and the relationship between damage and serology
might be stronger in uncontrolled disease [36].
Higher DAS28-P and worse mental health might identify
a group of patients with augmented central pain process-
ing, such as those with RA and concurrent FM [6, 7, 37]
who display less structural damage than those with RA
alone [38]. Our findings highlight the importance of non-
inflammatory mechanisms as moderators of disease as-
sessment, and prediction of erosive progression might be
improved by inclusion of DAS28-P and measures of
mental health.
Our study confirms relationships between RA and OA
radiographic features at baseline and their progression [1,
39]. RA or OA radiographic scoring achieves specificity by
inclusion of disease-characteristic joint groups (e.g. MCP
joints for RA and DIP joints for OA). Comparable with non-
RA populations, the predominant joints affected by OA in
our study were the DIP [25] and first MTP joints [26]).
However, either disease might affect joints that are
scored for the other disease. Associations between RA
and OA might reflect the propensity of both diseases to
cause cartilage damage and JSN [14], or effects of age
and other confounding factors. Prolonged synovitis and
erosive damage might eventually lead to co-occurring
OA [22], although this association was not apparent in
this early RA cohort. Similarly, OA at baseline did not sig-
nificantly moderate the risk of erosive damage over the
same period. In summary, OA can be considered a
comorbid condition in early RA. We show that comorbid
OA might influence inflammatory disease assessment in
RA, for example, by contributing to SJCs in the hands, or
to disability (foot OA).
Consistent with previous studies, radiographic OA was
associated with increasing age [40], and increasing age
was also associated with worse baseline RA radiographic
scores [41]. Older patients might present with more
advanced disease, perhaps because they might accept
joint symptoms as a sign of normal ageing. Peak RA inci-
dence has shifted to older age groups in recent decades,
and the burden of concurrent RA and OA is likely to further
increase. Lack of association between OA and BMI or
gender might reflect study power or moderating effects
of RA.
Interpretation of our data is subject to several methodo-
logical limitations. Radiographic scoring by a single obser-
ver eliminated interobserver variability, but similar results
might not be obtained by other investigators. RA and OA
features were scored separately, with more than several
weeks between scoring of the same films for respective
diseases. However, scorers cannot be blinded to concur-
rent radiographic features. All cortical disruptions were
scored as erosions [42], and uneven cortical bone sur-
faces adjacent to OST might have influenced RA radio-
graphic scoring. Scoring images in chronological
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sequence permits back-checking of difficult images, but
knowing that all participants had early RA might have led
us to overestimate radiographic progression.
ERAN documents a real-life inception cohort of people
who present to secondary care services with early RA,
and the frequency of radiographic assessment varied, al-
though inclusion of the follow-up period as a covariate did
not affect our conclusions. Study centre inclusion was not
random, and follow-up radiographs were available for only
a subgroup, who differed from the total ERAN population
in baseline disease activity and smoking, both of which
are risk factors for poor outcomes. Reported RA radio-
graphic scores in the current study are comparable with
those in some previous reports [43], but higher than in
others [44, 45]. Our included participants might have
had worse clinical features and undergone more frequent
radiographic follow-up, and our findings may be represen-
tative of those with more active RA. OA pathology might
precede radiographic change [46], and few people pro-
gressed to newly classified OA. Our findings apply
mainly to the progression of OA that was present at first
presentation with RA, and further research should inves-
tigate whether the presence of early RA affects OA
incidence.
In conclusion, OA is a common comorbidity in early RA,
and both RA and OA structural progression occur during
the first 3 years after diagnosis. Associations between RA
and OA structural changes indicate the potential for
comorbid OA to confound early RA disease assessment.
Inflammation mediates erosive progression, but non-
inflammatory factors moderate the ability of DAS28 to pre-
dict erosive progression in early RA. Holistic approaches
to RA management that address psychosocial factors and
comorbidities, as well as joint inflammation, are indicated.
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